麻薬s 巨大（な）s join the 追跡する to India

By Andrew Leach
Updated: 00:00 BST, 4 April 2004

?

FIRST （機の）カム call centres, then computer ソフトウェア 開発 and 財政上の 分析. Now it is 麻薬s 研究 that Western companies are planning to outsource to India.

European 麻薬s 巨大（な）s such as GlaxoSmithKline and AstraZeneca are building 同盟s a nd 増加するing 投資 in India, which is now 予測（する） to become a major centre for 臨床の 裁判，公判s.

About 1% of 全世界の 臨床の 裁判，公判s are 行為／行うd in India, but Cambridge-based consultancy Oxygen Healthcare 予報するs that this could rise to 10% in five years.

Director Sunil Shah said lower costs and a 高度に educated 全労働人口 would encourage the 傾向, but one of the biggest attractions was the 抱擁する pool of 可能性のある 患者s.

'One of the hardest 仕事s in 臨床の 裁判，公判s is 新採用するing the 患者s to take part, and if this can be 改善するd, 開発 can be 速度(を上げる）d up,' he said.

'The size of India's 全住民 and the prevalence of 確かな 病気s make the country an attractive 場所 for 麻薬s companies.'

GlaxoSmithKline recently formed an 同盟 with Ranbaxy, India's biggest 麻薬s company, to 研究 new 治療s.

ジーンズ-Pierre Garnier, 長，指導者 (n)役員／(a)執行力のある of GSK, said that 研究 and 開発 予算s went much その上の in India than in America or Europe because of lower costs.

The 協会 of the British 製薬の 産業 said India had （疑いを）晴らす attractions for Western companies.

広報担当者 Richard Ley said: 'India is more than likely to 現れる as a centre of 裁判，公判s. The country is very attractive for 研究 into 病気s such as tuberculosis, which is ありふれた there.'

AstraZeneca has a centre in Bangalore, where more than 100 scientists work on 薬／医学s for the developing world.

Last year it opened a new 施設 there to find new 治療s for TB, which is 診断するd in two million people a year in India and more than eight million 世界的な.